```mermaid
flowchart TD
MAPK["MAPK<br/>Pathway"]
PI3K["PI3K<br/>Kinase"]
AKT["AKT<br/>Serine/Threonine<br/>Kinase"]
MTOR["mTOR<br/>Mechanistic Target<br/>of Rapamycin"]
ERK["ERK<br/>Extracellular Signal<br/>Regulated Kinase"]
P38["p38<br/>Stress-Activated<br/>Protein Kinase"]
TNF["TNF-alpha<br/>Tumor Necrosis<br/>Factor Alpha"]
ALS["ALS<br/>Amyotrophic<br/>Lateral Sclerosis"]
Inflammation["Neuroinflammation<br/>Inflammatory<br/>Response"]
Cancer["Cancer<br/>Malignant<br/>Transformation"]
Tumor["Tumor<br/>Growth"]
Neuroprotection["Neuroprotection<br/>Cell Survival"]
Neurodegeneration["Neurodegeneration<br/>Cell Death"]
PI3K -->|"activates"| AKT
AKT -->|"activates"| MTOR
PI3K -->|"regulates"| MAPK
AKT -->|"regulates"| MAPK
MTOR -->|"regulates"| MAPK
ERK -->|"activates"| MAPK
P38 -->|"activates"| MAPK
TNF -->|"inhibits"| MAPK
TNF -->|"promotes"| Inflammation
MAPK -->|"promotes"| Neuroprotection
MAPK -->|"therapeutic_target"| ALS
MAPK -->|"therapeutic_target"| Neurodegeneration
Inflammation -->|"inhibits"| MAPK
MAPK -->|"activates"| Cancer
Cancer -->|"promotes"| Tumor
style MAPK fill:#006494
style PI3K fill:#4a1a6b
style AKT fill:#4a1a6b
style MTOR fill:#4a1a6b
style ERK fill:#4a1a6b
style P38 fill:#4a1a6b
style TNF fill:#ef5350
style Neuroprotection fill:#1b5e20
style ALS fill:#ef5350
style Inf
The Mitogen-Activated Protein Kinase (MAPK) signaling cascades represent a fundamental family of intracellular signaling pathways that regulate virtually every aspect of neuronal cell biology, from development and differentiation to survival, plasticity, and death. The MAPK pathway transduces extracellular signals into intracellular responses through a conserved three-tiered kinase cascade involving MAP kinase kinase kinases (MAP3Ks), MAP kinase kinases (MAP2Ks), and MAP kinases (MKs). These pathways play critical roles in neuronal homeostasis, synaptic plasticity, learning and memory, and the cellular response to stress. Dysregulation of MAPK signaling has emerged as a central mechanism in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders [@kim2024][@giovannini2023].
The MAPK family encompasses several distinct signaling cascades: the extracellular signal-regulated kinase (ERK) pathway, the c-Jun N-terminal kinase (JNK) pathway, and the p38 MAPK pathway. While these pathways share structural homology and some overlapping functions, they are activated by distinct stimuli and mediate different cellular outcomes. The ERK pathway is primarily associated with neurotrophic factor signaling and promotes neuronal survival and plasticity, whereas the JNK and p38 pathways are predominantly activated by cellular stress and promote inflammation and cell death [@si2022]. Understanding the complex interplay between these pathways provides critical insights into the molecular mechanisms underlying neurodegeneration and identifies potential therapeutic targets.
The ERK1/2 pathway, also known as the Ras-Raf-MEK-ERK cascade, is one of the most extensively studied MAPK pathways in the nervous system. This cascade is initiated by activation of receptor tyrosine kinases (RTKs) at the neuronal plasma membrane, including receptors for nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other growth factors [@huang2023]. Upon ligand binding, RTKs undergo dimerization and autophosphorylation, creating docking sites for adaptor proteins such as Shc (Src homology 2 domain-containing) and Grb2 (growth factor receptor-bound protein 2).
The signaling cascade proceeds through a series of protein kinases: Ras GTPase is recruited to the activated receptor complex and transitions from its inactive GDP-bound state to an active GTP-bound state. Activated Ras then recruits and activates Raf (MAP3K), which initiates the kinase cascade. Raf phosphorylates and activates MEK1/2 (MAP2K), which in turn phosphorylates and activates ERK1/2 (MAPK) [@roskoski2024]. Dual phosphorylation of ERK1/2 on threonine and tyrosine residues within the activation loop is required for full enzymatic activity. Once activated, ERK1/2 translocates to the nucleus where it phosphorylates and regulates the activity of various transcription factors, including Elk-1, c-Fos, and c-Myc, thereby controlling gene expression programs essential for neuronal survival and plasticity [@yoon2023].
The c-Jun N-terminal kinase (JNK) pathway is primarily activated by cellular stress rather than growth factor signaling. Diverse stress stimuli including oxidative stress, mitochondrial dysfunction, excitotoxicity, neuroinflammation, and DNA damage activate the JNK cascade [@davis2023]. The upstream activation involves activation of MAP3Ks such as ASK1 (apoptosis signal-regulating kinase 1) and MEKK1 (MEK kinase 1), which phosphorylate and activate MKK4 and MKK7, the MAP2Ks specific for JNK.
JNK exists in three isoforms: JNK1, JNK2, and JNK3. While JNK1 and JNK2 are expressed ubiquitously, JNK3 is expressed predominantly in the brain, making it particularly relevant to neurodegenerative processes [@brehme2024]. Once activated, JNK translocates to the nucleus where it phosphorylates c-Jun, JunD, and other components of the AP-1 (activator protein-1) transcription factor complex. JNK-mediated phosphorylation of c-Jun enhances its transcriptional activity and promotes expression of pro-apoptotic genes including BIM, PUMA, and Fas ligand [@dhanasekaran2023]. Additionally, JNK phosphorylates and regulates mitochondrial proteins, directly promoting mitochondrial dysfunction and release of cytochrome c.
The p38 MAPK pathway consists of four isoforms (p38α, p38β, p38γ, and p38δ), with p38α being the most abundantly expressed in the brain. Similar to JNK, p38 is activated by cellular stress including inflammatory cytokines, oxidative stress, and ischemia [@cuenda2023]. The canonical p38 cascade involves activation of MAP3Ks including TAK1 (transforming growth factor-beta-activated kinase 1) and MLK3 (mixed-lineage kinase 3), which phosphorylate and activate MKK3 and MKK6, the specific MAP2Ks for p38.
Activated p38 MAPK regulates numerous downstream targets including MAPKAP kinases (MK2, MK3), transcription factors (ATF2, CHOP), and cytoplasmic substrates. In neurons, p38 signaling contributes to synaptic dysfunction, excitotoxicity, and inflammatory responses in glial cells [@bachstetter2023]. The p38 pathway has been particularly implicated in the regulation of tau pathology in Alzheimer's disease, as p38 can directly phosphorylate tau at disease-relevant sites.
ERK1/2 signaling serves as a critical mediator of neurotrophic factor-induced neuronal survival. Nerve growth factor (NGF) binding to TrkA receptors activates the ERK pathway, promoting survival of sympathetic neurons and sensory neurons during development [@levental2024]. Brain-derived neurotrophic factor (BDNF) signaling through TrkB receptors similarly activates ERK, supporting survival of cortical and hippocampal neurons. The ERK pathway mediates neurotrophic effects through multiple mechanisms including phosphorylation of the pro-apoptotic protein BAD, activation of CREB (cAMP response element-binding protein)-dependent gene transcription, and upregulation of anti-apoptotic Bcl-2 family proteins [@numakawa2023].
In the adult brain, ERK signaling continues to play essential roles in synaptic plasticity, the cellular basis of learning and memory. Long-term potentiation (LTP), a persistent strengthening of synaptic connections believed to underlie memory formation, requires ERK activity in postsynaptic neurons [@thomas2024]. ERK phosphorylates and regulates NMDA receptor subunits, AMPA receptor trafficking proteins, and transcription factors that drive expression of plasticity-related genes. Inhibition of MEK (the upstream activator of ERK) blocks LTP induction and impairs spatial memory formation, demonstrating the critical importance of ERK signaling in cognitive function [@sweatt2023].
Despite its generally protective role, ERK signaling exhibits complex dysregulation in neurodegenerative diseases. In Alzheimer's disease, ERK activation shows a biphasic pattern: early stages show increased ERK activity possibly reflecting compensatory responses to pathology, while late stages exhibit decreased ERK signaling associated with synaptic loss and cognitive decline [@mendes2024]. This dichotomy highlights the context-dependent nature of ERK function in neurodegeneration.
Hyperactive ERK signaling can also contribute to pathology through inappropriate cell cycle re-entry. Post-mitotic neurons that re-enter the cell cycle are prone to die, and aberrant ERK activation has been implicated in triggering this pathological process [@khurana2023]. Furthermore, ERK-mediated phosphorylation of tau at serine and threonine residues contributes to neurofibrillary tangle formation, linking ERK signaling to a core pathological feature of Alzheimer's disease [@hanger2023].
In Alzheimer's disease, JNK3 is uniquely implicated due to its neuronal specificity. JNK3 is activated in vulnerable brain regions including the hippocampus and entorhinal cortex in AD patients, and JNK3 knockout mice show reduced neuronal apoptosis and improved cognitive function in AD models [@sclip2024]. JNK activation contributes to amyloid-beta (Aβ) toxicity through multiple mechanisms: JNK phosphorylates the amyloid precursor protein (APP) at sites that enhance amyloidogenic processing, and JNK activation promotes expression of pro-apoptotic genes that execute the cell death program [@colombo2023].
The JNK pathway also mediates synaptic dysfunction in AD. Chronic JNK activation impairs synaptic plasticity and contributes to spine loss, the structural correlate of cognitive decline. Studies demonstrate that JNK inhibition improves synaptic function and memory in animal models of AD, highlighting the therapeutic potential of targeting this pathway [@tai2024].
JNK signaling plays a particularly prominent role in Parkinson's disease, where it mediates dopaminergic neuron death triggered by mitochondrial toxins, alpha-synuclein pathology, and oxidative stress. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a mitochondrial complex I inhibitor that induces parkinsonian symptoms in humans and animals, potently activates the JNK pathway in dopaminergic neurons [@saporito2023]. JNK inhibition protects against MPTP-induced neurotoxicity, demonstrating a causal role for JNK in PD pathogenesis.
Alpha-synuclein aggregation, the pathological hallmark of PD, also activates JNK signaling. Oligomeric and fibrillar forms of alpha-synuclein trigger oxidative stress and mitochondrial dysfunction that activate the JNK pathway, creating a vicious cycle of pathology propagation [@kanda2024]. Additionally, JNK-mediated phosphorylation of alpha-synuclein at serine 129 promotes its aggregation, further linking JNK to PD pathogenesis.
In amyotrophic lateral sclerosis, JNK activation contributes to motor neuron death triggered by mutant SOD1 (superoxide dismutase 1) and other disease-causing proteins. JNK3 expression is upregulated in spinal cord motor neurons from ALS patients, and JNK inhibition extends survival in SOD1 mutant mice [@ranganathan2023]. The pathway mediates excitotoxic motor neuron death through regulation of glutamate receptor signaling and downstream pro-apoptotic effectors.
Huntington's disease, caused by mutant huntingtin protein with expanded polyglutamine repeats, also involves JNK pathway dysregulation. Mutant huntingtin activates JNK, and JNK inhibition reduces neurodegeneration in HD models [@zhang2024]. The pathway contributes to transcriptional dysregulation, mitochondrial dysfunction, and apoptosis characteristic of HD.
The p38 MAPK pathway plays a central role in regulating neuroinflammation, a key contributor to neurodegeneration across all major neurodegenerative diseases. In microglia, the resident immune cells of the brain, p38 signaling controls production of pro-inflammatory cytokines including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) [@lee2023]. Amyloid-beta, alpha-synuclein, and mutant huntingtin all activate microglial p38, triggering release of inflammatory mediators that promote neuronal dysfunction and death.
In Alzheimer's disease, p38 activation in microglia correlates with disease progression, and p38-mediated cytokine production contributes to tau pathology through activation of tau kinases [@zhang2024a]. Similarly, in Parkinson's disease, p38-driven neuroinflammation accelerates dopaminergic neuron loss. Therapeutic targeting of p38 to reduce neuroinflammation has been explored, though challenges remain in achieving beneficial effects without compromising normal immune function [@munoz2023].
Beyond its role in inflammation, p38 directly phosphorylates tau protein at multiple sites relevant to Alzheimer's disease neurofibrillary pathology. The p38α isoform phosphorylates tau at Thr181, Ser202, Thr205, Ser396, and Ser404, all sites that are hyperphosphorylated in brains of AD patients [@feuerbach2024]. This direct link between p38 and tau pathology makes the pathway an attractive therapeutic target.
Inhibition of p38 reduces tau phosphorylation in cellular and animal models, and improves cognitive function in tau transgenic mice [@ittner2023]. Combined approaches targeting both p38-mediated inflammation and tau pathology may prove particularly beneficial in AD treatment.
Prion diseases, including Creutzfeldt-Jakob disease (CJD), involve the conversion of normal cellular prion protein (PrP^C) to the pathogenic prion isoform (PrP^Sc). MAPK pathways are activated in prion disease, with JNK and p38 showing particularly strong activation in response to prion protein aggregation [@caughlin2024]. The resulting neuroinflammation and neuronal death share features with other neurodegenerative conditions, suggesting common downstream pathways.
Cerebrovascular disease contributes to vascular dementia, the second most common dementia type after Alzheimer's disease. MAPK signaling mediates the effects of vascular risk factors including hypertension, diabetes, and atherosclerosis on the brain. Chronic hypoperfusion activates JNK and p38 pathways in cerebral endothelial cells and neurons, contributing to white matter damage and cognitive decline [@iadecola2023].
MAPK pathways intersect with the autophagy-lysosome system, which is crucial for clearing misfolded proteins that accumulate in neurodegenerative diseases. ERK activation can stimulate autophagy through mTOR-independent pathways, while JNK activation regulates the autophagy protein Beclin-1 [@wang2024]. Dysregulation of these interactions contributes to impaired protein clearance in AD, PD, and related disorders.
The ubiquitin-proteasome system (UPS) is another critical pathway for protein clearance that interacts with MAPK signaling. JNK activation can promote degradation of misfolded proteins through activation of the UPS, though chronic JNK activation overwhelms this protective response [@tai2023]. Understanding these interactions provides insights into therapeutic strategies to enhance protein clearance.
Several genes linked to familial Parkinson's disease impact MAPK signaling. PINK1 (PTEN-induced kinase 1) and PARKIN, mutated in autosomal recessive PD, regulate mitochondrial quality control. Mitochondrial damage activates the JNK pathway, providing a link between genetic risk factors and pathway dysregulation [@pickrell2024]. LRRK2 (leucine-rich repeat kinase 2), the most common genetic cause of PD, interacts with MAPK pathways through various mechanisms.
APP and presenilin mutations that cause familial AD influence MAPK signaling. Amyloid-beta production activates JNK and p38 pathways, while presenilin mutations affect ERK signaling through altered Notch processing [@strooper2023]. The APOE4 allele, the major genetic risk factor for sporadic AD, is associated with increased JNK activation and inflammation.
Phosphorylation states of MAPK pathway components can serve as biomarkers of disease activity. Phospho-ERK, phospho-JNK, and phospho-p38 levels in cerebrospinal fluid and blood have been investigated as potential biomarkers for neurodegenerative diseases [@zetterberg2024]. These measures may help monitor disease progression and treatment responses.
Multiple clinical trials have evaluated MAPK pathway inhibitors for neurodegenerative diseases. JNK inhibitors have been tested in PD and ALS, though achieving adequate brain penetration remains challenging [@kalia2023]. p38 inhibitors have been explored for AD, targeting neuroinflammation. MEK inhibitors have shown mixed results in clinical trials for cognitive impairment.
The three major MAPK pathways do not operate in isolation but form an integrated network with extensive cross-talk. ERK signaling can inhibit JNK activation under some conditions, while JNK activation can suppress ERK signaling through various mechanisms [@cargnello2023]. This crosstalk creates context-dependent outcomes where the same stimulus can trigger different responses depending on the cellular state and pathway balance.
In neurodegeneration, the balance between pro-survival ERK signaling and pro-death JNK/p38 signaling emerges as a critical determinant of neuronal fate. Factors that shift this balance toward JNK/p38 activation promote neuronal death, while those that maintain ERK activity support survival. Understanding this balance provides insights into disease progression and identifies intervention points [@elion2024].
MAPK pathways integrate with numerous other signaling networks in neurons. Phosphoinositide 3-kinase (PI3K)/Akt signaling, another major pro-survival pathway, interacts with MAPK at multiple levels. Akt can phosphorylate and inhibit components of the pro-apoptotic machinery activated by JNK, providing a survival counterbalance [@manning2023]. mTOR signaling, which regulates protein synthesis and autophagy, also intersects with MAPK pathways in ways that influence neurodegeneration.
The centrality of MAPK dysregulation in neurodegeneration has driven extensive drug development efforts targeting these pathways. MEK inhibitors that block ERK activation have shown beneficial effects in animal models of AD and PD, though clinical translation has been challenging due to toxicity concerns [@cheng2024]. JNK inhibitors have demonstrated neuroprotective effects in preclinical models of PD, AD, and HD, but blood-brain barrier penetration has limited clinical development.
p38 inhibitors have been explored extensively for anti-inflammatory applications, with some compounds reaching clinical trials for rheumatoid arthritis. However, adverse effects have limited their utility, and neuroprotective benefits in neurodegenerative diseases remain to be established [@kumar2023].
Beyond direct kinase inhibitors, alternative approaches to modulate MAPK signaling are being explored. Gene therapy approaches to deliver MAPK pathway regulators, peptide inhibitors of specific MAPK interactions, and targeting of upstream activators offer potential advantages [@liu2024]. Natural compounds with MAPK-modulating properties, including curcumin, resveratrol, and flavonoids, are also under investigation for neuroprotective effects.
Advances in single-cell RNA sequencing and proteomics are revealing cell-type-specific patterns of MAPK pathway dysregulation in neurodegenerative diseases. These approaches identify which cell types contribute most to pathway alterations and may reveal novel therapeutic targets [@mathys2024].
Computational models integrating MAPK pathway interactions with other signaling networks and pathological processes are providing new insights into disease mechanisms. These models may predict optimal intervention points and combination therapy strategies [@chen2023].
The following diagram shows the key molecular relationships involving MAPK/ERK Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: